The Purple Sky Store
Women’s Tank Top
Women’s Tank Top
Couldn't load pickup availability
More than just a wardrobe staple, this tank supports an important cause. 40% of all revenue from the Empower Micro-Rib Tank goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing you to make a positive impact with every wear.
- 52% Airlume combed and ring-spun cotton, 48% polyester for a soft, durable feel
- Fabric weight: 5.4 oz./yd.² (183 g/m²)
- 1 × 1 micro-rib texture for a sleek fit
- Pre-shrunk with side-seamed construction for lasting shape
- Stretch fit with thick straps and a mid-length cut
Note: Wear this tank with pride, knowing you’re supporting pancreatic cancer research and making a difference.
Share











Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...